Abstract: The present disclosure relates to the generation of food grade sugar modified 1-MCP nanobubbles ranging in size from 50 to 600 nm. These nanobubbles have a high degree of stability while in aqueous solution and can inhibit the action of ethylene in different biological processes. In addition, they can reduce the action of ethylene in plant metabolism, making the plant less susceptible to water stress, low temperature stress, and stress from soil conditions, among others. This disclosure also relates to the method of preparing sugar modified 1-MCP nanobubbles, their different uses and applications.

Abstract: A pharmaceutical composition comprising: a) an effective amount of one or more lytic bacteriophages specific against Fusobacterium nucleatum selected from Fnp?02-14, Fnp?11 and Fnn?107 or mixtures of them; and b) one or more pharmaceutically acceptable carrier and/or excipients. Method for preventing and/or treating diseases associated with Fusobacterium nucleatum and the use of the pharmaceutical composition for treating a disease associated with Fusobacterium nucleatum of the oral cavity such as periodontal disease, among others.

Abstract: A sequential or cascading predictive control method is provided, including first solving a cost function and then a second cost function for two or more control objectives. The method includes separating the cost function into at least two or more cost functions, depending on the number of defined control objectives. The method additionally includes controlling a first variable with a unitary cost function, a single term or nature of the control objectives. The method also includes determining the possible states that minimize the cost of the first objective to be controlled. Considering only the options given through this determination, a second variable is controlled with a cost function that minimizes the cost function thereof.

Abstract: A pharmaceutical composition comprising: a) an effective amount of one or more lytic bacteriophages specific against Fusobacterium nucleatum selected from Fnp?02-14, Fnp?11 and Fnn?107 or mixtures of them; and b) one or more pharmaceutically acceptable carrier and/or excipients. Method for preventing and/or treating diseases associated with Fusobacterium nucleatum and the use of the pharmaceutical composition for treating a disease associated with Fusobacterium nucleatum of the oral cavity such as periodontal disease, among others.

Abstract: A multilevel converter allowing the reduction of volume and accessibility to the control and transformation of electric power, including at least two basic cells and having: a) a first power switch that interconnects a positive bus between the two basic cells connected in cascade each other; b) a second power switch that interconnects a negative bus between two basic cells connected in cascade each other and c) a capacitor with a third power switch, connected in series and interconnected between the positive and negative bus.

Abstract: A multilevel converter operating with fewer components saving costs, losses, size and weight, allowing the reduction of volume and accessibility to the control and transformation of electric power, comprising at least a basic cell formed by: a) a first power switch that interconnects the positive bus between said at least one basic cell and at least another basic cell connected in cascade each other and/or a basic cell and a continuous voltage source; b) a second power switch that interconnects the negative bus between said at least one basic cell and at least another basic cell connected in cascade each other; and/or a basic cell and the continuous voltage source of point a); and c) a capacitor with a third power switch, both of them being connected in series each other and interconnected between the positive and negative bus.

Abstract: A controlled release system includes a polymeric support, wherein the polymeric support is biodegradable; a polymeric matrix, wherein the polymeric matrix includes polyhydroalkanoate; and encapsulated gases or volatiles; and a controlled release system includes a polymeric support; a polymeric matrix, wherein the polymeric matrix includes (poly-3-hydroxybutyrate-co-3-hydroxyvalerate) and poly (?-caprolactone); and encapsulated gases or volatiles.

Abstract: The present invention is related to the use of compounds or pharmaceutically acceptable salts thereof that modulate astrocytic release of substances through connexin and pannexin hemichannels, for the treatment of psychiatric disorders. Compounds or pharmaceutically acceptable salts thereof used in the present invention comprise any compound that differentially modulates, blocks, opens, inhibits, and/or activates connexin and/or pannexin hemichannels from astrocytes while not affecting gap junctions. The invention is also related to a method for treating psychiatric disorders, comprising administering to a mammal or human a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof, that modulates astrocytic release of substances through connexin and pannexin hemichannels. Pharmaceutical compositions and a screening method are also considered in the present invention.